IPM Take
The sharp signal is that Europe is no longer treating cardiovascular disease as only a lifestyle or acute-care problem. The Safe Hearts Plan puts prevention, personalised monitoring, screening, AI and inequalities into the same political frame. That matters because cardiovascular personalised medicine will not be built around one test or one drug. It will depend on whether countries can identify risk early, act before complications and close the gap between Member States where cardiovascular death rates still differ dramatically.
Executive Summary
The European Commission unveiled the Safe Hearts Plan on 16 December 2025 as the first EU approach to cardiovascular disease. The plan supports Member States across prevention, early detection and screening, treatment, care and rehabilitation. It includes flagship initiatives on lifelong personalised and digitally enabled prevention, cardiovascular health checks, personalised treatment and monitoring, AI and digital tools, inequalities monitoring, and research and innovation. The Commission states that cardiovascular diseases claim 1.7 million lives each year in the EU and that cardiovascular deaths are eight times higher in some Member States than in others.
Why it matters
- Policymakers: Need to turn the EU plan into national cardiovascular strategies, funding mechanisms and measurable prevention targets.
- Public authorities: Must connect prevention, screening, treatment, rehabilitation, inequalities monitoring and digital infrastructure instead of treating them as separate workstreams.
- Clinicians / hospitals: Should prepare for stronger expectations around risk identification, cardiovascular health checks, personalised monitoring and integrated care.
Previously, European cardiovascular policy was often spread across prevention, tobacco control, nutrition, diabetes, obesity, acute care and national heart-health strategies. The Safe Hearts Plan tries to pull these pieces into a single EU agenda.
What has changed is the ambition to make cardiovascular prevention more personalised and digitally enabled. The plan is built around three pillars: prevention, early detection and screening, and treatment and care, including rehabilitation. These are supported by cross-cutting themes on digital innovation, research and knowledge, and tackling inequalities.
There is no single eligibility group. The affected population includes people at risk of cardiovascular disease, patients needing prevention or monitoring, and groups facing unequal access to care. The plan is especially relevant to cardiometabolic risk because it links cardiovascular prevention to diabetes, obesity and other modifiable risk factors.
The implementation question is whether Member States can turn EU-level ambition into national programmes, funded pathways and measurable outcomes. For IPM, the message is direct: cardiovascular prevention is becoming a readiness issue. Europe now needs to show that personalised prevention can be delivered at scale, not only promised in policy language.
